848004-52-4

Upstream product

• 848004-21-7 [2-(tert-butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-(2-isocyanato-4,5-dimethoxy-phenyl)-methanone 
• 848004-19-3 (2-amino-4,5-dimethoxy-phenyl)-[2-(tert-butyl-dimethyl-silanyloxymethyl)-pyrrolidin-1-yl]-methanone 
• 848004-50-2 (S)-2-(4-{2-[(S)-2-(tert-Butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carbonyl]-4,5-dimethoxy-phenylcarbamoyloxymethyl}-phenoxycarbonylamino)-pentanedioic acid diallyl ester 

Downstream Products

• 848004-54-6 2-[4-(11-hydroxy-7,8-dimethoxy-5-oxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyloxymethyl)-phenoxycarbonylamino]-pentanedioic acid diallyl ester 
• 848004-56-8 2-[4-(11-hydroxy-7,8-dimethoxy-5-oxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyloxymethyl)-phenoxycarbonylamino]-pentanedioic acid 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4] benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy

The design, synthesis and evaluation of four novel pyrrolo[2,1-c][1,4] benzodiazepine (PBD) prodrugs (1a,b and 2a,b; Fig. 1) for potential use in carboxypeptidase G2 (CPG2)-based antibody-directed enzyme prodrug therapy (ADEPT) is reported. Although all f

SYNTHESIS OF PROTECTED PYRROLOBENZODIAZEPINES

A method of synthesis of a N-10 protected PBD compound of formula (I) via an intermediate of formula (II) or formula (V).